Quince Therapeutics, Inc. Research and Development Expense
Quince Therapeutics, Inc. (QNCX) reported Research and Development Expense of $5.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Quince Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $5.46M, a 16.66% decline year-over-year.
- Quince Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $6.84M, a 15.96% decline year-over-year.
- Quince Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $12.60M, a 116.33% increase year-over-year.
- Quince Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $8.08M, a 64.42% increase year-over-year.
- Quince Therapeutics, Inc. research and development expense for fiscal 2025 was $35.38M, a 90.33% increase from fiscal 2024.
- Quince Therapeutics, Inc. research and development expense for fiscal 2024 was $18.59M, a 96.78% increase from fiscal 2023.
- Quince Therapeutics, Inc. research and development expense for fiscal 2023 was $9.45M, a 62.48% decline from fiscal 2022.
- Quince Therapeutics, Inc. research and development expense for fiscal 2022 was $25.18M, a 58.59% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.46M 10-Q · filed 2026-08-14 | $12.31M 10-Q · filed 2026-08-14 | $24.91M derived: sum of 3 quarters · filed 2026-08-14 | $32.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $6.84M 10-Q · filed 2026-05-11 | $19.45M derived: sum of 2 quarters · filed 2026-05-11 | $27.53M derived: sum of 3 quarters · filed 2026-05-11 | $34.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $12.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $20.68M derived: sum of 2 quarters · filed 2026-04-10 | $27.24M derived: sum of 3 quarters · filed 2026-08-14 | $35.38M 10-K · filed 2026-04-10 |
| 2025-09-30 | $8.08M 10-Q · filed 2025-11-12 | $14.64M derived: sum of 2 quarters · filed 2026-08-14 | $22.78M 10-Q · filed 2025-11-12 | $28.61M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $6.55M 10-Q · filed 2026-08-14 | $14.70M 10-Q · filed 2026-08-14 | $20.52M derived: sum of 3 quarters · filed 2026-08-14 | $25.44M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $8.14M 10-Q · filed 2026-05-11 | $13.97M derived: sum of 2 quarters · filed 2026-05-11 | $18.89M derived: sum of 3 quarters · filed 2026-05-11 | $23.03M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $10.74M derived: sum of 2 quarters · filed 2026-04-10 | $14.89M derived: sum of 3 quarters · filed 2026-04-10 | $18.59M 10-K · filed 2026-04-10 |
| 2024-09-30 | $4.92M 10-Q · filed 2025-11-12 | $9.06M derived: sum of 2 quarters · filed 2025-11-12 | $12.77M 10-Q · filed 2025-11-12 | $16.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.15M 10-Q · filed 2025-08-11 | $7.85M 10-Q · filed 2025-08-11 | $11.28M derived: sum of 3 quarters · filed 2025-08-11 | $12.71M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $3.70M 10-Q · filed 2025-05-13 | $7.14M derived: sum of 2 quarters · filed 2025-05-13 | $8.57M derived: sum of 3 quarters · filed 2025-05-13 | $9.92M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $4.87M derived: sum of 2 quarters · filed 2025-03-24 | $6.22M derived: sum of 3 quarters · filed 2025-03-24 | $9.45M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.43M 10-Q · filed 2024-11-13 | $2.78M derived: sum of 2 quarters · filed 2024-11-13 | $6.01M 10-Q · filed 2024-11-13 | $8.78M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.35M 10-Q · filed 2024-08-13 | $4.58M 10-Q · filed 2024-08-13 | $7.35M derived: sum of 3 quarters · filed 2024-08-13 | $9.80M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $3.23M 10-Q · filed 2024-05-13 | $6.00M derived: sum of 2 quarters · filed 2024-05-13 | $8.45M derived: sum of 3 quarters · filed 2024-05-13 | $15.65M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.22M derived: sum of 2 quarters · filed 2024-04-01 | $12.42M derived: sum of 3 quarters · filed 2024-04-01 | $25.18M 10-K · filed 2024-04-01 |
| 2022-09-30 | $2.45M 10-Q · filed 2023-11-14 | $9.65M derived: sum of 2 quarters · filed 2023-11-14 | $22.41M 10-Q · filed 2023-11-14 | $37.62M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $7.20M 10-Q · filed 2023-08-03 | $19.96M 10-Q · filed 2023-08-03 | $35.17M derived: sum of 3 quarters · filed 2023-08-03 | $49.21M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $12.76M 10-Q · filed 2023-05-15 | $27.97M derived: sum of 2 quarters · filed 2023-05-15 | $42.01M derived: sum of 3 quarters · filed 2023-05-15 | $56.73M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $15.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $29.25M derived: sum of 2 quarters · filed 2023-03-15 | $43.97M derived: sum of 3 quarters · filed 2023-03-15 | $60.80M 10-K · filed 2023-03-15 |
| 2021-09-30 | $14.04M 10-Q · filed 2022-11-09 | $28.76M derived: sum of 2 quarters · filed 2022-11-09 | $45.58M 10-Q · filed 2022-11-09 | $61.44M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $14.72M 10-Q · filed 2022-08-09 | $31.54M 10-Q · filed 2022-08-09 | $47.40M derived: sum of 3 quarters · filed 2022-08-09 | $64.38M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $16.82M 10-Q · filed 2022-05-10 | $32.68M derived: sum of 2 quarters · filed 2022-05-10 | $49.66M derived: sum of 3 quarters · filed 2022-05-10 | $63.75M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $32.84M derived: sum of 2 quarters · filed 2022-03-01 | $46.93M derived: sum of 3 quarters · filed 2022-03-01 | $61.31M 10-K · filed 2022-03-01 |
| 2020-09-30 | $16.98M 10-Q · filed 2021-10-29 | $31.07M derived: sum of 2 quarters · filed 2021-10-29 | $45.45M 10-Q · filed 2021-10-29 | $55.48M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $14.09M 10-Q · filed 2021-08-06 | $28.47M 10-Q · filed 2021-08-06 | $38.49M derived: sum of 3 quarters · filed 2022-03-01 | $46.75M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $14.38M 10-Q · filed 2021-05-06 | $24.41M derived: sum of 2 quarters · filed 2022-03-01 | $32.66M derived: sum of 3 quarters · filed 2022-03-01 | $39.77M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $10.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $18.28M derived: sum of 2 quarters · filed 2022-03-01 | $25.39M derived: sum of 3 quarters · filed 2022-03-01 | $30.21M 10-K · filed 2022-03-01 |
| 2019-09-30 | $8.25M 10-Q · filed 2020-11-12 | $15.36M derived: sum of 2 quarters · filed 2020-11-12 | $20.19M 10-Q · filed 2020-11-12 | $23.28M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $7.11M 10-Q · filed 2020-08-14 | $11.93M 10-Q · filed 2020-08-14 | $15.03M derived: sum of 3 quarters · filed 2021-03-01 | $17.32M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $4.83M 10-Q · filed 2020-05-12 | $7.92M derived: sum of 2 quarters · filed 2021-03-01 | $10.21M derived: sum of 3 quarters · filed 2021-03-01 | $12.50M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.39M derived: sum of 2 quarters · filed 2021-03-01 | $7.67M derived: sum of 3 quarters · filed 2021-03-01 | $10.09M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.29M 10-Q · filed 2019-11-12 | $4.58M derived: sum of 2 quarters · filed 2019-11-12 | $6.99M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $2.29M 10-Q · filed 2019-08-09 | $4.70M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $2.41M 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |